• Veracyte Aims to Expand Diagnostics Reach With $50M NanoString Deal

    9 days ago - By Xconomy

    Veracyte, a company whose tests help physicians make treatment decisions, is adding technology from NanoString to the fold to expand its diagnostic capabilities. South San Francisco-based Veracyte announced Tuesday that it has reached a deal for global rights to develop and commercialize diagnostics based on the nCounter FLEX system. The nCounter is a NanoString instrument used to analyze the activity of genes. According to terms of the agreement, Veracyte will pay NanoString $40 million in cash, plus an additional $10 million in Veracyte stock. NanoString could receive an additional $10...
    Read more ...